Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane
- PMID: 2715167
- PMCID: PMC12211694
- DOI: 10.1007/BF00397917
Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane
Abstract
The synthesis of the bisacetate (8), the bisdichloroacetate (9), the biscarbamate (10) and the bisphosphate (11) of the "partial" antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane (7) is described. In the case of 8-10 the introduction of ester functions slightly reduces the estrogen receptor affinity of 7. However, it was strongly diminished in 11. Compared with 7 the estrogenic potency of 8-11 is moderately increased. Compounds 8-11 cause a strong inhibition of the hormone-dependent MXT M3.2 mouse mammary tumor. Only 9 containing cytotoxic dichloroacetate groups shows a significantly better antitumor effect than 7.
References
-
- Angerer E von (1984) Development of new drugs for endocrine tumor chemotherapy. Cancer Treat Rev 11 (suppl A):147–153 - PubMed
-
- Borgna JL, Rochefort H (1980) High affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol Cell Endocrinol 20:71–85 - PubMed
-
- Chattaway FD, Saerens E (1920) n-Butyl chloroformiate and its derivatives. J Chem Soc 117:708–711
-
- Coezy E, Borgna JL, Rochefort H (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317–323 - PubMed
-
- Druckrey H (1952) Experimentelle Grundlagen der Chemotherapie des Krebses. Dtsch Med Wochenschr 77:1534–1537 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous